Tyra Biosciences Rises on Upcoming Mid-Stage Trial Data
Shares of Tyra Biosciences (TYRA) rose more than 13% in early trading after the company announced a conference call to release top-line results from a mid-stage trial for its lead drug candidate, dabogratinib, used in treating bladder cancer. The biotech firm is based in Carlsbad, California. The stock's performance marked one of its strongest intraday gains since January 2023, indicating investor optimism about the potential outcomes of the clinical data release. Dabogratinib has been under development for several years and represents a key focus area for Tyra Biosciences in oncology research.
Tickers: $TYRA
Topics: biotechnology bladder cancer dabogratinib TYRA stock movement